-
EP3169328
European procedure
Extract from the Register of European Patents
EP About this file: EP3169328
| EP3169328 - QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 13.01.2023 Database last updated on 26.04.2025 | |
| Former | The patent has been granted Status updated on 04.02.2022 | ||
| Former | Grant of patent is intended Status updated on 21.10.2021 | ||
| Former | Examination is in progress Status updated on 14.09.2021 | ||
| Former | Grant of patent is intended Status updated on 27.05.2021 | ||
| Former | Examination is in progress Status updated on 04.09.2019 | ||
| Former | Request for examination was made Status updated on 21.04.2017 | ||
| Former | The international publication has been made Status updated on 31.01.2017 | Most recent event Tooltip | 13.01.2023 | No opposition filed within time limit | published on 15.02.2023 [2023/07] | Applicant(s) | For all designated states ABIVAX 5 rue de la Baume 75008 Paris / FR | For all designated states Centre National de la Recherche Scientifique 3, rue Michel Ange 75794 Paris Cedex 16 / FR | For all designated states Institut Curie 26, rue d'Ulm 75248 Paris Cedex 05 / FR | For all designated states Université de Montpellier 163 Rue Auguste Broussonnet 34090 Montpellier / FR | [2017/21] | Inventor(s) | 01 /
TAZI, Jamal 4 rue Condorcet F-34380 Clapiers / FR | 02 /
NAJMAN, Romain 29b rue du 11 Novembre 1918 F-94240 L'Hay-les-Roses / FR | 03 /
MAHUTEAU, Florence 36 avenue Hoche F-78470 Saint Remy Les Chevreuses / FR | 04 /
SCHERRER, Didier 18 avenue de la Fée Mélusine F-34170 Castelnau Le Lez / FR | 05 /
HAHNE, Michael 33, rue Lakanal F-34090 Montpellier / FR | 06 /
CHEBLI, Karim 20, rue Boucarié F-34110 Frontignan / FR | [2017/21] | Representative(s) | Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR | [N/P] |
| Former [2017/21] | Nony 11 rue Saint-Georges 75009 Paris / FR | Application number, filing date | 15738916.4 | 17.07.2015 | [2017/21] | WO2015EP66458 | Priority number, date | EP20140306164 | 17.07.2014 Original published format: EP 14306164 | [2017/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016009065 | Date: | 21.01.2016 | Language: | EN | [2016/03] | Type: | A2 Application without search report | No.: | EP3169328 | Date: | 24.05.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.01.2016 takes the place of the publication of the European patent application. | [2017/21] | Type: | B1 Patent specification | No.: | EP3169328 | Date: | 09.03.2022 | Language: | EN | [2022/10] | Search report(s) | International search report - published on: | EP | 24.03.2016 | Classification | IPC: | A61K31/47, A61K31/4709, A61K31/497, A61K31/5377, G01N33/50, C07D401/12, C07D215/38, C12Q1/6883, A61P1/04, A61P1/00, A61P9/10, // A61P11/00, A61P11/06, A61P17/00, A61P17/06, A61P19/02, A61P21/00, A61P25/00, A61P25/16, A61P25/28, A61P29/00, A61P35/00, A61P37/06 | [2021/21] | CPC: |
C07D215/38 (EP,CN,RU,US);
A61K31/47 (EP,KR,RU,US);
C12Q1/6883 (EP,CN,KR,US);
C07D401/12 (EP,CN,RU,US);
A61K31/4709 (EP,KR,RU,US);
A61K31/496 (RU);
A61K31/497 (EP,RU,US);
A61K31/5377 (EP,RU,US);
A61P1/00 (EP);
A61P1/04 (EP,RU);
A61P11/00 (EP);
A61P11/06 (EP);
A61P17/00 (EP,RU);
A61P17/06 (EP);
A61P19/02 (EP,RU);
A61P21/00 (EP);
A61P25/00 (EP,RU);
A61P25/16 (EP);
A61P25/28 (EP);
A61P29/00 (EP,KR,RU);
A61P35/00 (EP);
A61P37/06 (EP,RU);
A61P9/10 (EP);
C07D401/14 (RU);
C07D413/12 (RU);
C07D413/14 (RU);
C07F9/60 (CN);
C07F9/65583 (CN);
C12Q1/6874 (KR);
G01N33/5023 (EP,CN,US);
G01N33/5055 (EP,CN,US);
C12Q2600/136 (EP,CN,KR,US);
C12Q2600/158 (EP,CN,KR,US);
C12Q2600/178 (EP,CN,KR,US)
(-)
|
| Former IPC [2017/21] | A61K31/47, A61K31/4709, A61K31/497, A61K31/5377, C07D215/38, A61P29/00, A61P1/00, A61P19/02, A61P25/00, G01N33/50, C12Q1/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/21] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | CHINOLINDERIVATE ZUR BEHANDLUNG VON ENTZÜNDUNGSKRANKHEITEN | [2017/21] | English: | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | [2017/21] | French: | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | [2021/21] |
| Former [2017/21] | DÉRIVÉS DE QUINOLÉINE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES | Entry into regional phase | 17.02.2017 | National basic fee paid | 17.02.2017 | Designation fee(s) paid | 17.02.2017 | Examination fee paid | Examination procedure | 30.01.2017 | Date on which the examining division has become responsible | 17.02.2017 | Examination requested [2017/21] | 04.09.2017 | Amendment by applicant (claims and/or description) | 09.09.2019 | Despatch of a communication from the examining division (Time limit: M06) | 03.03.2020 | Reply to a communication from the examining division | 13.07.2020 | Despatch of a communication from the examining division (Time limit: M06) | 17.11.2020 | Reply to a communication from the examining division | 28.05.2021 | Communication of intention to grant the patent | 14.09.2021 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 21.10.2021 | Communication of intention to grant the patent | 27.01.2022 | Fee for grant paid | 27.01.2022 | Fee for publishing/printing paid | 27.01.2022 | Receipt of the translation of the claim(s) | Divisional application(s) | EP21211115.7 / EP3998070 | Opposition(s) | 12.12.2022 | No opposition filed within time limit [2023/07] | Fees paid | Renewal fee | 31.07.2017 | Renewal fee patent year 03 | 31.07.2018 | Renewal fee patent year 04 | 31.07.2019 | Renewal fee patent year 05 | 31.07.2020 | Renewal fee patent year 06 | 02.08.2021 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 09.03.2022 | [2023/02] |
| Former [2022/49] | SK | 09.03.2022 | |
| SM | 09.03.2022 | ||
| Former [2022/47] | SM | 09.03.2022 | Cited in | International search | [X]JPS5272821 (MITSUBISHI PETROCHEMICAL CO); | [I]WO2004007461 (PRANA BIOTECHNOLOGY LTD [AU], et al); | [I]WO2007103162 (SAMARITAN PHARMACEUTICALS INC [US], et al); | [X]US2009227628 (KOLCZEWSKI SABINE [DE], et al); | [A]WO2010127208 (FOREST LAB HOLDINGS LTD, et al); | [X]WO2010143168 (SPLICOS SOC [FR], et al); | [X]EP2465502 (SPLICOS SOC [FR], et al); | [I]US2012202870 (WEINER HOWARD [US], et al); | [XP]WO2014111892 (SPLICOS [FR], et al); | [XP]WO2015001518 (SPLICOS [FR], et al); | Examination | WO2015131019 |